How My VYVGART Path helped me get on treatment

Rene was diagnosed with anti-AChR antibody positive generalized myasthenia gravis (gMG) in 1981 and started on VYVGART for intravenous (IV) infusion in 2022. In this guest post, he explains how the Patient Support Program, My VYVGART Path, helped him navigate insurance, cost, and coverage questions after he was prescribed VYVGART.

Rene
Started on VYVGART for IV infusion in 2022

Rene is a paid spokesperson of argenx.

I remember checking for traffic before crossing a street and seeing two cars on top of each other. The double vision didn’t pass, and my friends on the volleyball team had to help me walk the rest of the way home. I didn’t realize it then, but gMG had changed my life forever. I was only 21 years old.

Up until that moment, my life seemed normal. I was born and raised in Colombia and played volleyball in college while I studied Civil Engineering. I was in my fourth year when the blurred and double vision started. I began wearing an eye patch, but the symptoms were so inconsistent that I was constantly switching the eye it would cover. Something was off. Then the symptoms progressed to the rest of my body and my volleyball days were over. I’d sit down to rest and think, “This is nothing I had planned for.”


“Figuring out insurance, cost, and coverage can be a complicated process, and I had two keys for success.”


Finally, I saw a neurologist who ran a test and diagnosed me with anti-AChR antibody positive gMG. After more than 40 years of trying different treatment options, I saw a commercial for VYVGART for IV infusion on TV. My doctor and I decided that I should try it, and I was prescribed VYVGART for IV infusion. Before I started, my doctor explained that the most common side effects are respiratory tract infection, headache, and urinary tract infection.

Figuring out insurance, cost and coverage can be a complicated process, and I had two keys for success. The first was my doctor, who submitted the paperwork to the insurance company and signed me up for My VYVGART Path. The other was Cyndi, my Nurse Case Manager at My VYVGART Path, who provided me with resources on navigating the insurance process. She was a fantastic resource for me.

Already prescribed VYVGART, but not signed up for My VYVGART Path?

Download the patient enrollment form to get started!

Once I was prescribed VYVGART, Cyndi sent me a welcome kit with resources for my treatment journey and called me to introduce herself. I could tell right away that she was going to be a great resource during my treatment journey. She was extremely nice and friendly. She described what I could expect from my treatment journey. From there, it only took about 2-3 weeks for the insurance to approve coverage for my VYVGART prescription.

There’s a lot that a Nurse Case Manager does behind the scenes that may help you get on treatment sooner. First, they’ll do a benefits verification to find out what your insurance covers. Next, they’ll help you determine your treatment location. For me, this was already taken care of because my doctor and I decided to use the infusion center at the hospital where he worked. Nurse Case Managers can also educate you on the prior authorization process, which is also called a pre-approval.

Download the “What’s Next?” guide to see how a Nurse Case Manager can provide resources to help you navigate the insurance process.

Luckily, I wasn’t denied coverage. But it’s reassuring to know that if that had happened, Cyndi would have provided me with information on the appeals process and helped me understand potential financial assistance programs. For instance, with the VYVGART Co-pay Program, I might have paid as little as zero dollars for VYVGART and related administration costs, depending on my eligibility.


“I believe that open communication set me up for success with getting on my VYVGART treatment.”


As I reflect on that time before I started my first treatment, my biggest takeaway is that communication is the key. Since the doctor submits the forms to the insurance company, I made sure that I was talking to him as much as possible to help him build that case. And, once I was prescribed, I know that talking to Cyndi about the insurance process made all the difference to getting me on treatment sooner.

I believe that open communication set me up for success with getting on my VYVGART treatment. I’ve been able to do some of the normal things in my life again, like ride my bike. The volleyball player in me from all those years ago is happy that I am able to be more active.

Information provided by the Nurse Case Managers is not intended or implied to be a substitute for professional medical advice, diagnosis, or treatment. Always consult with a qualified and licensed physician or other healthcare provider regarding your medical condition, treatment, and healthcare needs.

AChR=acetylcholine receptor; gMG=generalized myasthenia gravis; IV=intravenous


VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Subcutaneous Injection 180 mg/mL and 2000 U/mL vial; VYVGART (efgartigimod alfa-fcab) Injection for Intravenous Use 400 mg/20 mL vial
VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Subcutaneous Injection 180 mg/mL and 2000 U/mL vial; VYVGART (efgartigimod alfa-fcab) Injection for Intravenous Use 400 mg/20 mL vial

Still have questions? Call 1-833-VYVGART (1-833-898-4278) to speak with an educator about gMG, how VYVGART works, study data, cost and coverage, and more.

Do not use VYVGART if you have a serious allergy to efgartigimod alfa or any of the other ingredients in VYVGART. Do not use VYVGART HYTRULO if you have a serious allergy to efgartigimod alfa, hyaluronidase, or any of the other ingredients in VYVGART HYTRULO. VYVGART and VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.

VYVGART and VYVGART HYTRULO may cause serious side effects, including:

  • Infection. VYVGART and VYVGART HYTRULO may increase the risk of infection. The most common infections for efgartigimod alfa-fcab-treated patients were urinary tract and respiratory tract infections. Signs or symptoms of an infection may include fever, chills, frequent and/or painful urination, cough, pain and blockage of nasal passages/sinus, wheezing, shortness of breath, fatigue, sore throat, excess phlegm, nasal discharge, back pain, and/or chest pain.
  • Allergic Reactions (hypersensitivity reactions). VYVGART and VYVGART HYTRULO can cause allergic reactions such as rashes, swelling under the skin, and shortness of breath. Hives were also observed in patients treated with VYVGART HYTRULO. Serious allergic reactions, such as trouble breathing and decrease in blood pressure leading to fainting have been reported with efgartigimod alfa-fcab.
  • Infusion-Related Reactions. VYVGART and VYVGART HYTRULO can cause infusion-related reactions. The most frequent symptoms and signs reported with efgartigimod alfa-fcab were high blood pressure, chills, shivering, and chest, abdominal, and back pain.

Tell your doctor if you have signs or symptoms of an infection, allergic reaction, or infusion-related reaction. These can happen while you are receiving your VYVGART or VYVGART HYTRULO treatment or afterward. Your doctor may need to pause or stop your treatment. Contact your doctor immediately if you have signs or symptoms of a serious allergic reaction.

Before taking VYVGART or VYVGART HYTRULO, tell your doctor if you:

  • take any medicines, including prescription and non-prescription medicines, supplements, or herbal medicines,
  • have received or are scheduled to receive a vaccine (immunization), or
  • have any allergies or medical conditions, including if you are pregnant or planning to become pregnant, or are breastfeeding.

What are the common side effects of VYVGART and VYVGART HYTRULO?

The most common side effects in efgartigimod-alfa-fcab-treated patients were respiratory tract infection, headache, and urinary tract infection. Additional common side effects with VYVGART HYTRULO are injection site reactions, including rash, redness of the skin, itching sensation, bruising, pain, and hives.

These are not all the possible side effects of VYVGART and VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to the US Food and Drug Administration at 1-800-FDA-1088.

What is VYVGART® (efgartigimod alfa-fcab) for intravenous (IV) infusion and what is VYVGART® HYTRULO (efgartigimod alfa and hyaluronidase-qvfc) for subcutaneous injection?

VYVGART and VYVGART HYTRULO are both prescription medicines, each used to treat a condition called generalized myasthenia gravis, which causes muscles to tire and weaken easily throughout the body, in adults who are positive for antibodies directed toward a protein called acetylcholine receptor (anti-AChR antibody positive).

Please see the full Prescribing Information for VYVGART and the full Prescribing Information for VYVGART HYTRULO, and talk to your doctor.

Do not use VYVGART if you have a serious allergy to efgartigimod alfa or any of the other ingredients in VYVGART. Do not use VYVGART HYTRULO if you have a serious allergy to efgartigimod alfa, hyaluronidase, or any of the other ingredients in VYVGART HYTRULO. VYVGART and VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.

VYVGART and VYVGART HYTRULO may cause serious side effects, including:

  • Infection. VYVGART and VYVGART HYTRULO may increase the risk of infection. The most common infections for efgartigimod alfa-fcab-treated patients were urinary tract and respiratory tract infections. Signs or symptoms of an infection may include fever, chills, frequent and/or painful urination, cough, pain and blockage of nasal passages/sinus, wheezing, shortness of breath, fatigue, sore throat, excess phlegm, nasal discharge, back pain, and/or chest pain.
  • Allergic Reactions (hypersensitivity reactions). VYVGART and VYVGART HYTRULO can cause allergic reactions such as rashes, swelling under the skin, and shortness of breath. Hives were also observed in patients treated with VYVGART HYTRULO. Serious allergic reactions, such as trouble breathing and decrease in blood pressure leading to fainting have been reported with efgartigimod alfa-fcab.
  • Infusion-Related Reactions. VYVGART and VYVGART HYTRULO can cause infusion-related reactions. The most frequent symptoms and signs reported with efgartigimod alfa-fcab were high blood pressure, chills, shivering, and chest, abdominal, and back pain.

Tell your doctor if you have signs or symptoms of an infection, allergic reaction, or infusion-related reaction. These can happen while you are receiving your VYVGART or VYVGART HYTRULO treatment or afterward. Your doctor may need to pause or stop your treatment. Contact your doctor immediately if you have signs or symptoms of a serious allergic reaction.

Before taking VYVGART or VYVGART HYTRULO, tell your doctor if you:

  • take any medicines, including prescription and non-prescription medicines, supplements, or herbal medicines,
  • have received or are scheduled to receive a vaccine (immunization), or
  • have any allergies or medical conditions, including if you are pregnant or planning to become pregnant, or are breastfeeding.

What are the common side effects of VYVGART and VYVGART HYTRULO?

The most common side effects in efgartigimod-alfa-fcab-treated patients were respiratory tract infection, headache, and urinary tract infection. Additional common side effects with VYVGART HYTRULO are injection site reactions, including rash, redness of the skin, itching sensation, bruising, pain, and hives.

These are not all the possible side effects of VYVGART and VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to the US Food and Drug Administration at 1-800-FDA-1088.

What is VYVGART® (efgartigimod alfa-fcab) for intravenous (IV) infusion and what is VYVGART® HYTRULO (efgartigimod alfa and hyaluronidase-qvfc) for subcutaneous injection?

VYVGART and VYVGART HYTRULO are both prescription medicines, each used to treat a condition called generalized myasthenia gravis, which causes muscles to tire and weaken easily throughout the body, in adults who are positive for antibodies directed toward a protein called acetylcholine receptor (anti-AChR antibody positive).

Please see the full Prescribing Information for VYVGART and the full Prescribing Information for VYVGART HYTRULO, and talk to your doctor.